Ribosomal S6 Kinase (RSK) Inhibitor

Ribosomal S6 Kinase (RSK) Inhibitors (48):

Cat. No.	Product Name	Effect	Purity

HY-156498

RMC-7977	Inhibitor	99.48%
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (K_d = 195 nM) and KRAS (G12V) (K_d = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS^G12C cancer models, and demonstrates good tolerability across various RAS cancer models.

HY-10510

BI-D1870	Inhibitor	99.72%
BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC₅₀s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively.

HY-N0643

Carnosol	Inhibitor	99.90%
Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC₅₀ of ~5.5 μM. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1).

HY-15773

PF-4708671	Inhibitor	99.85%
PF-4708671 is a potent cell-permeable S6K1 inhibitor with a K_i of 20 nM and IC₅₀ of 160 nM.

HY-N0418

Quercitrin	Inhibitor	99.72%
Quercitrin (Quercetin 3-rhamnoside) is a bioflavonoid compound with potential anti-inflammation, antioxidative and neuroprotective effect. Quercitrin induces apoptosis of colon cancer cells. Quercitrin can be used for the research of cardiovascular and neurological disease research.

HY-132891A

RSK4-IN-1 TFA	Inhibitor
RSK4-IN-1 TFA is a potent RSK4 inhibitor with a IC₅₀ value of 9.5 nM. RSK4-IN-1 TFA has antitumor activity.

HY-N0643R

Carnosol (Standard)	Inhibitor
Carnosol (Standard) is the analytical standard of Carnosol. This product is intended for research and analytical applications. Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC₅₀ of ~5.5 μM. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1).

HY-N0418R

Quercitrin (Standard)	Inhibitor
Quercitrin (Standard) is the analytical standard of Quercitrin. This product is intended for research and analytical applications. Quercitrin (Quercetin 3-rhamnoside) is a bioflavonoid compound with potential anti-inflammation, antioxidative and neuroprotective effect. Quercitrin induces apoptosis of colon cancer cells. Quercitrin can be used for the research of cardiovascular and neurological disease research.

HY-136848

SM1-71	Inhibitor
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a K_i of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.

HY-12493A

LY-2584702 tosylate salt	Inhibitor	98.58%
LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC₅₀ of 4 nM. In S6K1 enzyme assay, the IC₅₀ of LY-2584702 is 2 nM.

HY-19712

LJH685	Inhibitor	99.99%
LJH685 is a potent, ATP-competitive and selective RSK inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC₅₀s of 6, 5, 4 nM, respectively.

HY-B0167A

Sodium Salicylate	Inhibitor	99.93%
Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.

HY-15237

SL 0101-1	Inhibitor	≥98.0%
SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC₅₀ of 89 nM. SL 0101-1 (SL0101) is a selective RSK1/2 inhibitor, with a K_i of 1 μM.

HY-19713

LJI308	Inhibitor	99.07%
LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC₅₀s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.

HY-12059

AT7867	Inhibitor	99.88%
AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-10579

Pluripotin	Inhibitor	98.86%
Pluripotin is a dual inhibitor of ERK1 and RasGAP with K_Ds of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC₅₀s of 0.5, 2.5, 3.3, and 10.0 μM, respectively.

HY-133028

CKI-7 free base	Inhibitor	99.34%
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC₅₀ of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.

HY-100501

M2698	Inhibitor	99.87%
M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC₅₀s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.

HY-16071

AT13148	Inhibitor	99.21%
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

HY-52101A

FMK	Inhibitor	99.45%
FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.

Name
Email *

	Sorry, but the email address you supplied was invalid.